Daiichi Sankyo Initiates Phase 1/2 Clinical Trial of CD37-Targeted ADC DS3790a in 420 Patients with Hematologic Malignancies

▎Armstrong

On October 24, 2025, Daiichi Sankyo registered a Phase 1/2 clinical trial for DS3790a in the treatment of hematologic tumors on the Clinicaltrials.gov website.

This Phase 1/2 clinical trial plans to enroll 420 patients with advanced hematological malignancies and is expected to be completed in 2023.

According to the publicly available financial report of Daiichi Sankyo's second quarter (July-September), DS3790 is a CD37 ADC. The Phase 1/2 clinical expansion portion plans to explore monotherapy and various combination therapies, with the primary endpoint being CRR and secondary endpoints including ORR, BOR, DCR, etc.

Summary

CD37 is an important potential therapeutic target for AML. Several antibody drugs have advanced to the clinical stage previously, but no breakthroughs were achieved, including AbbVie’s introduction of Genmab's CD37 bispecific antibody. Apart from Daiichi Sankyo, Heidelberg's CD37 ADC is in the dose escalation phase of Phase I clinical trials, but its development has been put on hold as they seek partnerships.